Paula Bos
Has grant
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Paula Bos is an Associate Professor at Virginia Commonwealth University. Her research focuses on the roles of regulatory T cells in breast cancer progression and the development of brain metastasis cell lines. She aims to advance understanding in cancer biology through her recent publications and contributions to the field.
Recent Grants
Grant: Close
Investigating the Impact of Immune and Brain Cells Communication on Brain Metastasis
Open Date: 2024-08-12
Close Date: 2026-08-11
Grant: Open
Integrative Training Program in Cancer Biology
Open Date: 2023-07-01
Close Date: 2028-06-30
Grant: Open
Regulatory T cell modulation of reactive astrogliosis in brain metastasis
Open Date: 2022-06-01
Close Date: 2027-05-31
Grant: Close
Regulation of breast cancer progression by Treg cells
Open Date: 2022-01-01
Close Date: 2025-12-31
Grant: Close
Mechanistic dissection of immune cell effects on tumor cell behaviour.
Open Date: 2022-01-01
Close Date: 2022-12-31
Articles (3)
There is a significant sex bias in lung cancer, with males showing increased mortality compared with females. A better mechanistic understanding of these differences could help identify therapeutic targets to personalize cancer therapies to each sex. After observing a clear sex bias in humanized mice, with male patient-derived xenograft lung tumors being more progressive and deadlier than female patient-derived xenograft lung tumors, we identified mouse tumor models of lung cancer with the same sex bias. This sex bias was not observed in models of breast, colon, melanoma, and renal cancers. In vivo , the sex bias in growth and lethality required intact ovaries, functional innate NK cells and monocytes/macrophages, and the activating receptor NKG2D. Ex vivo cell culture models were sensitized to the anticancer effects of NKG2D-mediated NK cell and macrophage killing through the TRAIL–Bcl-XL axis when cultured with serum from female mice with intact ovaries. In both flank and orthotopic models, the Bcl-XL inhibitor navitoclax (ABT-263) improved tumor growth control in female mice and required NK cells, macrophages, and the TRAIL signaling pathway. This research suggests that navitoclax and TRAIL pathway agonists could be used as a personalized therapy to improve outcomes in women with lung cancer. Significance: Lung cancers in females are more susceptible to killing through a TRAIL–Bcl-XL axis, indicating that targeting this axis therapeutically could represent a personalized approach to treat female patients with lung cancer.
Year:
2024
Year:
2020
Year:
2020
Collaborators (8)
Xiang-Yang Wang
University of Virginia School of Medicine
Dipankar Bandyopadhyay
Virginia Commonwealth University
Raghavendra Pillappa
-
Joseph Landry
Associate Professor
Virginia Commonwealth University
Anthony Faber
Professor
Virginia Commonwealth University
Howard Li
Physician/Assistant Chief of Pulmonary
Oscar G. Johnson VA Medical Center
Rebecca Martin
Associate Professor
Virginia Commonwealth University
Jennifer Koblinski
Assistant professor, Director Cancer Mouse Models Core
Virginia Commonwealth University
Make your next move.
Prepare your application
Review drafts before you send them.